SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo

VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment. However, currently most of these anticancer drugs suffer some adverse effects. Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed. In this investigati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2011-07, Vol.17 (13), p.4439-4450
Hauptverfasser: Zhang, Shuang, Cao, Zhixing, Tian, Hongwei, Shen, Guobo, Ma, Yongping, Xie, Huanzhang, Liu, Yalin, Zhao, Chengjian, Deng, Senyi, Yang, Yang, Zheng, Renlin, Li, Weiwei, Zhang, Na, Liu, Shengyong, Wang, Wei, Dai, Lixia, Shi, Shuai, Cheng, Lin, Pan, Youli, Feng, Shan, Zhao, Xia, Deng, Hongxin, Yang, Shengyong, Wei, Yuquan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!